Hepatitis

A late-stage clinical trial assessing the safety and effectiveness of Mirum Pharmaceuticals’ brelovitug for adults with chronic hepatitis D has completed enrollment, and…

In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…

One-time treatment with VRON-0200 reduced hepatitis B virus (HBV) levels in the blood of most people with chronic hepatitis B — early trial findings…

Efforts to eliminate new hepatitis C cases by 2030, a goal set by the World Health Organization (WHO), are falling short in high-risk groups,…

A new test that uses a tiny drop of blood collected from a finger prick and returns results in about an hour can detect…

Dosing has begun in a Phase 1/2 clinical trial testing CRMA-1001, Nchroma Bio’s experimental epigenetic therapy being studied as a potential functional cure for…

Huahui Health‘s Libevitug has become the first approved treatment for chronic hepatitis D virus (HDV) infection in China. The country’s National Medical Products Administration…

After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly nine out of 10 evaluable…

Bepirovirsen added to standard-of-care medications led to higher functional cure rates for people with chronic hepatitis B than standard treatments alone, according to top-line…

Health Canada has expanded its approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir), making it the first eight-week, pan-genotypic treatment available for both acute and…